#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Type 2 diabetes mellitus Breast cancer metastatic Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Marginal zone lymphoma refractory Ewing's sarcoma recurrent Mastocytosis PIK3CA related overgrowth spectrum Systemic lupus erythematosus Sjogren's syndrome Aspergillus infection Erythema Small cell lung cancer limited stage Extra-osseous Ewing's sarcoma recurrent Fibrous dysplasia of bone Subarachnoid haemorrhage Measles Neurofibroma Plasma cell myeloma More trials…

    Learn about Rare Diseases

    Encephalitis autoimmune – Trials in Disease Familial amyotrophic lateral sclerosis – Basic Information Basal cell naevus syndrome – Life with Disease Factor IX deficiency – Basic Information Synovial sarcoma recurrent Thrombotic thrombocytopenic purpura Krabbe’s disease – Trials in Disease Friedreich’s ataxia – Trials in Disease Familial haemophagocytic lymphohistiocytosis – Treatment Immunodeficiency congenital – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Annamycin Melatonin Peginterferon Beta-1A Doxycycline Minoxidil DUVELISIB Nedosiran ZINC CHLORIDE Phenprocoumon Technetium (99Mtc) Ezetimibe Pp1493 Pseudoephedrine Hydrochloride Lepidoglyphus Destructor Transpocart19 Neflamapimod Ublituximab Rondaptivon Pegol Lebrikizumab Fluoroestradiol F-18 More therapies…

    Learn about Your Condition

    Choroid melanoma Haemoglobinuria Hyperplasia adrenal Endometrial stromal sarcoma Plasma cell myeloma recurrent Mantle cell lymphoma stage II Diphtheria Caesarean section Hypertonic bladder Glioma Abortion threatened Malignant melanoma Peripheral artery angioplasty CDKL5 deficiency disorder Neuroendocrine tumour More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Istituto Oncologico Veneto

Istituto Oncologico Veneto

Via Gattamelata 64, Padua, 35128, Italy

Want to learn more about this study or check if you can participate? Contact us.

  • Study on Pembrolizumab for Patients with High-Risk Stage III Melanoma After Surgery

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Malignant melanoma stage III
    Investigated Drugs:
    • Pembrolizumab
    Austria Belgium Denmark Finland France Germany +7

  • Study Comparing Trastuzumab Deruxtecan and Trastuzumab Emtansine for Patients with High-Risk HER2-Positive Breast Cancer with Residual Disease After Initial Treatment

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • HER2 positive breast cancer
    Investigated Drugs:
    • Trastuzumab Deruxtecan
    • Trastuzumab Emtansine
    Belgium Czechia Denmark France Germany Greece +7

  • Study on Alpelisib and Fulvestrant for Men and Postmenopausal Women with Advanced HR-positive, HER2-negative Breast Cancer with PIK3CA Mutation

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Breast cancer
    Investigated Drugs:
    • Alpelisib
    • Fulvestrant
    Belgium Bulgaria Czechia Denmark Finland France +10

  • Study on Durvalumab, Tremelimumab, and Enfortumab Vedotin for Patients with Muscle Invasive Bladder Cancer Ineligible or Refusing Cisplatin

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Bladder cancer
    Investigated Drugs:
    • Durvalumab
    • Enfortumab Vedotin
    • Infliximab
    Austria France Germany Greece Italy The Netherlands +3

  • Study of Vorasidenib for Patients with Residual or Recurrent Grade 2 Glioma with IDH1 or IDH2 Mutation

    Not recruiting

    3 1
    Investigated Diseases:
    • Glioma
    Investigated Drugs:
    • Vorasidenib
    France Germany Italy The Netherlands Spain

  • Study of Tepotinib for Patients with Advanced Lung Cancer with MET Exon 14 Skipping Alterations or MET Amplification

    Not recruiting

    2 1 1
    Investigated Drugs:
    • Tepotinib
    Belgium France Germany Italy The Netherlands Poland +1

  • Study Comparing Pembrolizumab and Placebo for Patients with Resected High-Risk Stage II Melanoma

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Malignant melanoma
    Investigated Drugs:
    • Pembrolizumab
    Belgium France Germany Italy Poland Spain

  • Study of Lurbinectedin and Doxorubicin for First-line Treatment in Patients with Metastatic Leiomyosarcoma

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Dexamethasone Sodium Phosphate
    • Doxorubicin Hydrochloride
    • Filgrastim
    Austria Belgium France Germany Italy The Netherlands +3

  • Study on Hepatocellular Carcinoma: Evaluating Livmoniplimab and Budigalimab for Patients with Advanced or Metastatic Cancer After First-Line Treatment

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Hepatocellular carcinoma
    Investigated Drugs:
    • Budigalimab
    • Lenvatinib
    • Livmoniplimab
    France Italy Spain

  • Study of Immunotherapy Combinations Including Zimberelimab for Patients With Advanced Non-Small Cell Lung Cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    Investigated Drugs:
    • Carboplatin
    • Cisplatin
    • Docetaxel
    France Italy Poland Spain
Previous Page
1 … 35 36 37 38 39 … 42
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!